4th ANNUAL MSK
SYMPOSIUM ON LYMPHOMA
State-of-the-Art in Biology, Therapy, and Patient Care
MAY 10-11, 2019
Memorial Sloan Kettering Cancer Center
Zuckerman Research Center
New York, NY
This symposium will feature updated information on lymphoma biology, diagnosis, immunology, and genetics, and ongoing efforts to translate the scientific discoveries into novel treatment strategies for a variety of lymphomas. Faculty will review the current standard of care and present their own perspectives on how they treat various types of lymphomas. Participants will have the opportunity to discuss diagnostic and management cases, and how to incorporate biologic and genetic biomarkers into clinical practice and clinical trials.

**Educational Objectives**
- Provide up-to-date information on recent molecular diagnostic methods
- Provide up-to-date information on recent updates to lymphoma pathology classification
- Provide up-to-date information on recent treatment options for patients with Hodgkin and non-Hodgkin lymphoma

**Target Audience**
This symposium is designed for medical and radiation oncologists, hematopathologists, scientists, and medical trainees involved in diagnosis, treatment, and biomedical research of lymphoma.

**MSK Course Director**

Anas Younes, MD  
Chief, Lymphoma Service

**MSK Organizing Committee**
Ahmet Dogan, MD, PhD  
Hans Guido Wendel, MD  
Joachim Yahalom, MD, FACP  
Andrew Zelenetz, MD, PhD

**MSK Course Faculty**
Maria E. Arcila, MD  
Connie Lee Batlevi, MD, PhD  
Steven M. Horwitz, MD  
Erel Joffe, MD  
Anita Kumar, MD  
Ross L. Levine, MD  
Sham Mailankody, MBBS

**Invited Course Faculty**
Philippe Armand, MD, PhD  
Dana-Farber Cancer Institute  
Boston, MA

Elias Campo, MD  
University of Barcelona  
Spain

Riccardo Dalla-Favera, MD  
Columbia University  
New York, NY

Andrew M. Evens, DO, MSc, FACP  
Rutgers Cancer Institute of New Jersey  
New Brunswick, NJ

Massimo Federico, MD  
University of Modena and Reggio Emilia  
Italy

Jude Fitzgibbon, PhD  
Barts Cancer Institute  
England

Michele Ghieilmini, MD  
Oncology Institute of Southern Switzerland  
Switzerland

Steven Le Gouill, MD  
University of Nantes  
France

Michael R. Green  
The University of Texas  
MD Anderson Cancer Center  
Houston, TX

**Wonderful program and speakers; looking forward to next year’s Symposium.**
- 2018 Course Attendee

Participants are invited to join the entire course faculty for a networking cocktail reception on Friday evening from 5:00-6:00 pm at Zuckerman Research Center.
Is there a Compelling Role for Hematopoietic Cell Transplantation in Early Relapsed or Refractory Follicular Lymphoma?

Friday, May 10, 12:00-1:00 PM

This luncheon will feature updated information on treatment of hematological malignancies during the dawn of the era of immunotherapies in the form of checkpoint inhibitors and chimeric antigen receptor (CAR) T cells. Faculty will review the current standard curative therapy (hematopoietic cell transplantation) and how it has evolved. Participants will have the opportunity to ask questions regarding diagnosis and management, and how to determine treatment standards for the best chance of cure.

Educational Objectives

• Provide up-to-date information regarding treatment options for patients with early relapsed or refractory Follicular Lymphoma.
• Provide an interactive discussion on potential risks with HCT and non-HCT treatments for hematologic malignancies.

Myeloma Luncheon Panel

Advances in the Treatment and Monitoring of Multiple Myeloma

Saturday, May 11, 12:30-1:30 PM

This luncheon will provide information on use of CAR-T therapy in myeloma and methods to detect low levels of disease by mass spectrometry. Faculty will provide their perspective on the future of these techniques in multiple myeloma. Participants will have the opportunity to discuss how to incorporate these new approaches into clinical practice and clinical trials.

Target Audience

This luncheon is intended for medical and radiation oncologists, hematopathologists, scientists, and medical trainees involved in diagnosis, treatment, and biomedical research of hematological malignancies.

Educational Objectives

• Understand current data and future directions for CAR T therapy for multiple myeloma.
• Describe the steps to measure immunoglobulins by mass spectrometry.
• List the advantages and disadvantages of MALDI-TOF and QTOF.

Space is limited for the luncheons and RSVP is required during course registration: mskcc.org/LymphomaCourse
Symposium Agenda

Friday, May 10

7:30 AM BREAKFAST & REGISTRATION

Department of Medicine Grand Rounds

8:00 AM Introduction and Welcoming Remarks
Anas Younes, MD

8:05 AM The Molecular Pathogenesis of DLBCL
Riccardo Dalla-Favera, MD

9:00 AM State of the Lymphoma at MSK
Anas Younes, MD

Diffuse Large B Cell Lymphoma
MODERATOR: Andrew D. Zelenetz, MD, PhD

9:40 AM Evolving Frontline Therapy of DLBCL
Laurie Sehn, MD, MPH

10:00 AM CAR T cell Therapy for Lymphoma
Helen Heslop, MD, DSc (Hon)

10:20 AM Primary Mediastinal and Grey Zone Lymphoma
Pier-Luigi Zinzani, PhD

10:40 AM Novel Endpoints in Clinical Trials
Andrew D. Zelenetz, MD, PhD

11:00 AM Identification of DLBL Subtypes Requiring Novel Therapy
Peter Johnson MA, MD, FRCP

11:20 AM Whole Genome Sequencing in DLBCL and FL
Ralf Küppers, PhD

11:40 AM Panel Discussion

12:00 PM LUNCH BREAK

Adult BMT Luncheon Panel (Debate)*

12:00 PM LUNCH & WELCOME

12:10 PM Hematopoietic Cell Transplantation in Early Relapsed or Refractory Follicular Lymphoma: PRO STANCE
Gunjan L. Shah, MD

12:30 PM Hematopoietic Cell Transplantation in Early Relapsed or Refractory Follicular Lymphoma: CON STANCE
Connie Lee Batlevi, MD, PhD

12:50 PM Voting, Q&A, and Closing Remarks

Follicular Lymphoma (FL): Biology
MODERATOR: Hans-Guido Wendel, MD

1:00 PM Novel Molecular Targets in FL
Hans-Guido Wendel, MD

1:20 PM New Insights Into the Biology of Germinal Center Lymphomas
Jude Fitzgibbon, PhD

1:40 PM Targeting the Epigenome of Follicular Lymphoma
Michael R. Green

2:00 PM Current and Novel Treatment Approaches to FL
Massimo Federico, MD

2:20 PM Intercepting FL with Low Tumor Burden
Michele Ghielmini, MD

2:40 PM Role of Radiation Therapy
Joachim Yahalom, MD, FACR

3:00 PM What Can We Learn from Rare FL Variants
David M. Weinstock, MD

3:20 PM Panel Discussion

3:40 PM BREAK

Mantle Cell Lymphoma
MODERATOR: Ariela Noy, MD

4:00 PM Biology of MCL
Elias Campo, MD

4:20 PM Management of Newly Diagnose MCL: Are We Ready for Chemo Free Approach
Steven Le Gouill, MD

4:40 PM Outcome of Relapsed MCL in the Modern Era
Anita Kumar, MD

5:00 PM Panel Discussion

5:20 PM ADJOURN

Networking Cocktail Reception*
Participants are invited to join course director, Dr. Anas Younes, and the entire course faculty for a cocktail reception on Friday evening from 5:20-6:30 PM at Zuckerman Research Center.

*Space is limited for the luncheons and RSVP is required during course registration.

*Please RSVP during course registration
## Symposium Agenda

**Saturday, May 11**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>7:30 AM</td>
<td>BREAKFAST</td>
</tr>
<tr>
<td>8:00 AM</td>
<td><strong>Clinical Application of Genome Sequencing</strong></td>
</tr>
<tr>
<td></td>
<td><strong>MODERATOR:</strong> Ahmet Dogan, MD, PhD</td>
</tr>
<tr>
<td>8:00 AM</td>
<td>Introduction to Clinical Diagnostic Genome Sequencing</td>
</tr>
<tr>
<td></td>
<td>Maria E. Arcila, MD</td>
</tr>
<tr>
<td>8:30 AM</td>
<td>Clonal Hematopoiesis</td>
</tr>
<tr>
<td></td>
<td>Ross L. Levine, MD</td>
</tr>
<tr>
<td>9:00 AM</td>
<td>Molecular Classification of DLBCL</td>
</tr>
<tr>
<td></td>
<td>Louis M. Staudt, MD</td>
</tr>
<tr>
<td>9:30 AM</td>
<td>Can We Apply DLBCL Genetic Classification to Targeted Sequencing Panels</td>
</tr>
<tr>
<td></td>
<td>Erel Joffe, MD</td>
</tr>
<tr>
<td>9:45 AM</td>
<td>Panel Discussion</td>
</tr>
<tr>
<td>10:15 AM</td>
<td>BREAK</td>
</tr>
<tr>
<td>10:30 AM</td>
<td><strong>Hodgkin Lymphoma</strong></td>
</tr>
<tr>
<td></td>
<td><strong>MODERATOR:</strong> Anas Younes, MD</td>
</tr>
<tr>
<td>10:30 AM</td>
<td>Frontline Therapy</td>
</tr>
<tr>
<td></td>
<td>David J.Straus, MD</td>
</tr>
<tr>
<td>10:50 AM</td>
<td>Checkpoint Inhibitors</td>
</tr>
<tr>
<td></td>
<td>Philippe Armand, MD</td>
</tr>
<tr>
<td>11:10 AM</td>
<td>Therapy of Relapsed HL</td>
</tr>
<tr>
<td></td>
<td>Alison J. Moskowitz, MD</td>
</tr>
<tr>
<td>11:30 AM</td>
<td>HL in the Elderly</td>
</tr>
<tr>
<td></td>
<td>Andrew M. Evens, DO, MSc, FACP</td>
</tr>
<tr>
<td>11:50 AM</td>
<td>Panel Discussion</td>
</tr>
<tr>
<td>12:30 PM</td>
<td>LUNCH BREAK</td>
</tr>
<tr>
<td></td>
<td><strong>Myeloma Luncheon Panel</strong></td>
</tr>
<tr>
<td>12:30 PM</td>
<td>LUNCH &amp; WELCOME</td>
</tr>
<tr>
<td>12:40 PM</td>
<td>CAR T cell Therapy for Multiple Myeloma</td>
</tr>
<tr>
<td></td>
<td>Sham Mailankody, MBBS</td>
</tr>
<tr>
<td>1:00 PM</td>
<td>Mass Spectrometry for the Detection of Monoclonal Immunoglobulins</td>
</tr>
<tr>
<td></td>
<td>Katie Thoren, MD</td>
</tr>
<tr>
<td>1:20 PM</td>
<td>Q&amp;A and Closing Remarks</td>
</tr>
</tbody>
</table>

**T Cell Lymphoma**

**MODERATOR:** Steven M. Horwitz, MD

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>1:30 PM</td>
<td>Therapy of Newly Diagnosed Patients</td>
</tr>
<tr>
<td></td>
<td>Steven M. Horwitz, MD</td>
</tr>
<tr>
<td>2:00 PM</td>
<td>Immune Receptor Signals in T Cell Lymphoma</td>
</tr>
<tr>
<td></td>
<td>Jürgen Ruland, MD</td>
</tr>
<tr>
<td>2:30 PM</td>
<td>Panel Discussion</td>
</tr>
<tr>
<td>3:00 PM</td>
<td>BREAK</td>
</tr>
</tbody>
</table>

**Marginal Zone, Waldenstrom, and Rare Lymphomas**

**MODERATOR:** M. Lia Palomba, MD

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>3:20 PM</td>
<td>Molecular Biology of Rare Lymphoma Subtypes</td>
</tr>
<tr>
<td></td>
<td>Reiner Siebert, MD</td>
</tr>
<tr>
<td>3:40 PM</td>
<td>Marginal Zone Lymphoma</td>
</tr>
<tr>
<td></td>
<td>Ariela Noy, MD</td>
</tr>
<tr>
<td>4:00 PM</td>
<td>Waldenstrom Macroglobulinemia</td>
</tr>
<tr>
<td></td>
<td>M. Lia Palomba, MD</td>
</tr>
<tr>
<td>4:20 PM</td>
<td>Panel Discussion</td>
</tr>
<tr>
<td>4:45 PM</td>
<td>Closing Remarks</td>
</tr>
<tr>
<td></td>
<td>Anas Younes, MD</td>
</tr>
<tr>
<td>5:00 PM</td>
<td>ADJOURN</td>
</tr>
</tbody>
</table>

### Live Simulcast Available

We are pleased to offer a live simulcast for the 4th Annual MSK Symposium on Lymphoma, available to attendees unable to attend this course in person. CME credit will still be offered for the live simulcast and active participation is required throughout the symposium. We do hope you will attend in person but understand that can sometimes be a challenge so we are happy to offer the live simulcast as an option.

Please visit mskcc.org/LymphomaCourse for details or to register.

*Space is limited for the luncheons and RSVP is required during course registration.*
Registration

REGISTRATION FEES

<table>
<thead>
<tr>
<th></th>
<th>EARLY*</th>
<th>GENERAL</th>
</tr>
</thead>
<tbody>
<tr>
<td>Physicians (MDs, PhDs, and DOs)</td>
<td>$350</td>
<td>$400</td>
</tr>
<tr>
<td>Nurses, PAs, and Other Healthcare Professionals</td>
<td>$150</td>
<td>$200</td>
</tr>
<tr>
<td>Residents and Fellows</td>
<td>$100</td>
<td>$150</td>
</tr>
<tr>
<td>Industry Professionals**</td>
<td>$650</td>
<td>$700</td>
</tr>
</tbody>
</table>

*Early registration rate expires January 31, 2019.
**Industry and Professionals may attend CME activities for their own education. Marketing, sales, and promotion of products and services is strictly prohibited at MSK CME activities.

Register online:
mskcc.org/LymphomaCourse

Registration includes continental breakfast, lunch, and refreshment breaks. Please contact cme@mskcc.org at least one week prior to the course if you have any special dietary needs.

• 30% Discounted Rate for MSK Alumni and MSK Alliance Members: MSK offers a 30% discounted rate to all MSK Alumni and MSK Alliance members to attend a CME course. Please contact cme@mskcc.org for promotion code or more information.

• MSK Staff Registration: Registration is complimentary for MSK staff. However, you must register online: mskcc.org/LymphomaCourse.

Accreditation Statement

MSK is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

AMA Credit Designation Statement

MSK designates this live activity for a maximum of 17.50 AMA PRA Category 1 Credits™. Physicians should claim only credit commensurate with the extent of their participation in the activity.

Faculty Disclosure

It is the policy of MSK to make every effort to ensure balance, independence, objectivity, and scientific rigor in all continuing medical education activities it offers as an ACCME accredited provider. In accordance with ACCME guidelines and standards, all faculty participating in an activity provided by MSK are expected to disclose any significant financial interest or other relationship with the manufacturer of any commercial product and/or provider of commercial services which are discussed by them in an educational presentation. As required by the ACCME, when an unlabeled use of a commercial product or an investigational use not yet approved for any purpose is discussed during an educational activity, MSK requires the speaker to disclose that the product is not labeled for the use under discussion or that the product is still investigational.

Symposium Location

Memorial Sloan Kettering Cancer Center
Zuckerman Research Center
417 East 68th Street
New York, NY 10065

Accommodations

MSK has negotiated special rates and amenities at select hotels in Manhattan. For information on hotels in the vicinity of MSK with discounted rates, please visit: mskcc.org/cme.

Contact

Memorial Sloan Kettering Cancer Center
Office of Continuing Medical Education
646-227-2025
cme@mskcc.org